Profile of perampanel and its potential in the treatment of partial onset seizures

Details

Serval ID
serval:BIB_502C706C67BB
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Profile of perampanel and its potential in the treatment of partial onset seizures
Journal
Neuropsychiatr Dis Treat
Author(s)
Rheims S., Ryvlin P.
ISSN
1176-6328 (Print)
ISSN-L
1176-6328
Publication state
Published
Issued date
2013
Volume
9
Pages
629-37
Language
english
Notes
Rheims, Sylvain
Ryvlin, Philippe
eng
New Zealand
Neuropsychiatr Dis Treat. 2013;9:629-37. doi: 10.2147/NDT.S30129. Epub 2013 May 13.
Abstract
Perampanel (PER) is a novel antiepileptic compound that decreases neuronal excitability by modulating glutamatergic transmission through selective noncompetitive blockade of AMPA receptors. PER has been evaluated in three pivotal placebo-controlled randomized trials as adjunctive therapy in adult drug-resistant partial epilepsy. In comparison to placebo, adjunctive PER effectively reduces seizure frequency. The relative risk of the responder rate (95% confidence interval [CI]) was thus 1.60 (1.08-2.36), 1.79 (1.42-2.25) and 1.66 (1.24-2.23) for once-daily PER 4 mg/day, 8 mg/day and 12 mg/day, respectively. The most common adverse events associated with PER were nonspecific central nervous system side effects. Some concerns have been raised about risk of clinically significant weight gain and of psychiatric adverse events. Long-term open-label extensions of the three pivotal trials are underway. PER has recently been approved both in Europe and in the USA for the adjunctive treatment of partial onset seizures in patients aged 12 years and above. However, in the absence of a direct comparison between PER and other licensed antiepileptic drugs' efficacy and tolerability, the clinical advantages of PER over the other drugs in intractable partial epilepsy remains to be determined.
Keywords
antiepileptic drug, epilepsy, partial seizures, perampanel
Pubmed
Open Access
Yes
Create date
29/11/2018 12:37
Last modification date
20/08/2019 14:06
Usage data